Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Canadian scientists made life-saving contributions during the COVID-19 pandemic

This year, the Nobel Prize in physiology or medicine will be awarded on Oct. 3. Canada will be in the spotlight again, thanks to Canadian scientists’ involvement with mRNA vaccine development.

The Conversation

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 35 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Take whatever COVID booster you can get, says head of EU drugs watchdog

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections.

Reuters

Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More…

Reuters

Benzinga

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Salon

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Singapore grants interim approval for Moderna's bivalent Covid booster vaccine

SINGAPORE: Singapore on Wednesday granted interim authorisation for a bivalent Covid-19 booster vaccine made by Moderna, the government said in a statement.

Bangkok Post

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Asharq Al-Awsat

Covid-19 boosters: Immunologists answer 5 key questions about the new shots

What is different about the updated booster shots? Two scientists offer their expertise to answer five questions about the shots.

Inverse

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 20 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022

Benzinga

It looks like we’ll be getting a COVID vaccine every year soon

America is trying a “new approach,” Biden said.

Mic

EU regulator gives green light to omicron booster vaccines

The European Medicines Agency (EMA) has backed two separate Covid-19 booster vaccines updated to target the omicron variant of Covid-19 and developed by drugmakers Moderna and BioNTech-Pfizer.

Radio France Internationale

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Revealed: Worst big City funds have lost £10 billion

The ten worst performing big City funds have lost investors £10 billion since Christmas, the latest blow to the reputation of the active investment sector.

Los Angeles Times

CDC advisers endorse booster shots that target omicron for Americans 12 and up

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

The Conversation

Will omicron-specific booster shots be more effective at combating COVID-19? 5 questions answered

On Sept. 1, 2022, the Centers for Disease Control and Prevention endorsed the use of updated COVID-19 booster shots that are specifically tailored to combat the two most prevalent omicron subvariants, BA.4 and BA.5. The decision comes just a day after the Food and Drug Administration’s emergency use authorization of…

Benzinga

Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash…

Wall Street Journal

Get all your
news in one place.

100's of premium titles.
One news app.

Inverse

What are the side effects of the new Covid-19 bivalent booster?

Last week, the FDA authorized both Pfizer and Moderna's Omicron-specific jabs. Experts say to get them as soon as they are available to you.

The Independent UK

US clears updated COVID boosters targeting newest variants

U.S. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain

Roll Call

FDA greenlights new COVID-19 booster despite limited data - Roll Call

The Food and Drug Administration granted emergency authorization to Pfizer and Moderna for updated COVID-19 booster shots.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Benzinga

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Axios

Moderna's COVID vaccine lawsuit looks ahead to future markets

Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets

Los Angeles Times

Omicron COVID-19 booster shots are coming: What you need to know

The next generation of COVID-19 booster shots — tailored specifically to combat the highly infectious family of omicron subvariants — could roll out early next month.

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.